Navigation Links
Evotec AG: R&D Update on 16 October 2007 Live on the Internet
Date:10/9/2007

HAMBURG, Germany and OXFORD, England, October 9 /PRNewswire-FirstCall/ -- Evotec AG (Frankfurt Stock Exchange: EVT) is going to hold an R&D Update in London on Tuesday 16 October 2007 at 13.00 pm BST (14.00 pm CET, 08.00 am US time East Coast) which will be broadcast live on the internet.

Jorn Aldag, (President & Chief Executive Officer), Dr John Kemp, (Chief Research & Development Officer) and Dr Tim Tasker, (EVP Clinical Development) will provide an update on the status and development plans for Evotec's Clinical Programs and Discovery Projects. In addition, we are delighted to announce that Dr Michael G Kelly, (SVP Research & Development) at Renovis, will present the Renovis Pipeline Programs.

To join the audio webcast and to access the presentation slides you will find a link on our home page http://www.evotec.com shortly before the event.

For those who prefer to listen to the presentation via phone, please dial:

From Europe: +49(0)69-5007-1308 (Germany)

+44(0)20-7806-1956 (UK)

From the US: +1-718-354-1388

Pass Code: 2793143

The on-demand version of the webcast will be available on our website: http://www.evotec.com - Investors - Webcasts.

About Evotec AG

Evotec is a leader in the discovery and development of novel small molecule drugs. Both through its own discovery programmes and through research collaborations, the Company is generating the highest quality research results to its partners in the pharmaceutical and biotechnology industries.

In proprietary projects, Evotec specialises in finding new treatments for diseases of the Central Nervous System. Evotec has three programmes in clinical development: EVT 201, a partial positive allosteric modulator (pPAM) of the GABAA receptor complex for the treatment of insomnia, EVT 101, a subtype selective NMDA receptor antagonist fo
'/>"/>

SOURCE Evotec AG
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Merge unveils updated medical imaging software
2. Merge announces sofware updates, upcoming acquisition
3. Tech Digest: Merge eMed product updates; Renaissance Learning 3rd qtr results
4. Solinus updates MailFoundry anti-spam hardware, switching to Linux
5. Dane County mapping software updated, available to public
6. Wingra Technologies updates data migration software
7. Firstlogics mailing-address update system gains Postal Service certification
8. Lands End Debuts Updated Virtual Model
9. Internet-enabled niche markets take center stage
10. Emergence of Internet video is changing the regulatory landscape
11. Viewing the Internet as a free-for-all can be costly
Post Your Comments:
*Name:
*Comment:
*Email:
Other Biology Technology:Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases 2Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases 3Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases 4Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases 5Genmab Discloses Target and Development Plans for HuMax-Inflam 2Genmab Discloses Target and Development Plans for HuMax-Inflam 3New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA 2New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA 3New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA 4